From their first introduction in 2011, this approach, in which antibodies are used to block key inhibitory receptor checkpoints CTLA-4, PD-1 on T cells, and PD-L1 on tumour cells, has led them to be used as first-line treatments for several cancers, with more clinical trials in progress. Here, CTLA4 is linked to cancer.